home / stock / cing / cing news

CING News and Press, Cingulate Inc. From 05/12/22

Stock Information
Company Name: Cingulate Inc.
Stock Symbol: CING
Market: NASDAQ
Website: cingulate.com
Menu
CING CING Quote CING Short CING News CING Articles CING Message Board
Get CING Alerts

News, Short Squeeze, Breakout and More Instantly...
CING - Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business Update

KANSAS CITY, Kan., May 12, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmace...
CING - Cingulate (CING) NobleCon18 Presentation Replay

Cingulate (CING) formal corporate presentation from NobleCon18 - Noble Capital Markets 18th Annual Small & Microcap Investor Conference - April 2022. Read More >>

CING - Cingulate Presents at NobleCon18

KANSAS CITY, Kan., April 26, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharma...

CING - JNCE and RPID among healthcare movers

Gainers: Eiger BioPharmaceuticals (EIGR) +36%. Cyteir Therapeutics (CYT) +30%. PAVmed (PAVM) +28%. Cingulate (CING) +26%. Bone Biologics (OTCPK:BBLG) +22%. Losers: Incannex Healthcare Limited (IXHL) -12%. Jounce Therapeutics (JNCE) -9%. Rapid Micro Biosystems (RPID) -...
CING - Cingulate GAAP EPS of -$0.32

Cingulate press release (NASDAQ:CING): Q4 GAAP EPS of -$0.32. As of December 31, 2021, Cingulate had $16.5 million in cash and cash equivalents. Based on the Company’s current operating plan, Cingulate expects its cash and cash equivalents as of December 31, 2021 will enable the Compan...

CING - Cingulate Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Clinical and Business Update

Completed Initial Public Offering, Raising Gross Proceeds of $25.0 Million Expedited Clinical Program for CTx-1301 Expected to Reduce Capital Requirements and Time to Approval KANSAS CITY, Kan., March 10, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-s...

CING - Cingulate to Present at Aegis Virtual Conference

KANSAS CITY, Kan., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmac...
CING - Cingulate Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD)

KANSAS CITY, Kan., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmac...

CING - Cingulate Appoints Curt Medeiros and Gregg Givens to Board of Directors

KANSAS CITY, Kan., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Following its initial public offering last month, Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build...

CING - Aegis Capital Corp. acted as Lead Bookrunning Manager on a $25 Million Initial Public Offering of Common Stock for Cingulate Inc. (NASDAQ: CING)

NEW YORK, NY / ACCESSWIRE / December 10, 2021 / Aegis Capital Corp. acted as Lead Bookrunning Manager on a $25 Million Initial Public Offering of Common Stock for Cingulate Inc. (NASDAQ:CING). Cingulate Inc. Cingulate Inc. is a clinical-stage biopharmaceutical company utilizing its pro...
Previous 10 Next 10